Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Asherie

Showing results (31-40 of 36) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 36 results.
Haematologica|July 2, 2016
Specific antibody deficiency and autoinflammatory disease extend the clinical and immunological spectrum of heterozygous NFKB1 loss-of-function mutations in humansCyrill Schipp, Schafiq Nabhani, Kirsten Bienemann, et al.
International Journal of Molecular Sciences|April 14, 2026
Viral Reactivation in Multiple Myeloma Patients Receiving Anti-BCMA Chimeric Antigen Receptor T-Cell TherapyIdo Cohen, Eyal Lebel, Sigal Grisariu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 9, 2024
Efficacy and Safety of Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T-Cell for the Treatment of Relapsed and Refractory AL AmyloidosisEyal Lebel, Nathalie Asherie, Shlomit Kfir-Erenfeld, et al.
Blood Advances|May 20, 2024
Clinical evaluation and determinants of response to HBI0101 (BCMA CART) therapy in relapsed/refractory multiple myelomaShlomit Kfir-Erenfeld, Nathalie Asherie, Eyal Lebel, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 7, 2026
B-cell Maturation Antigen Targeted Chimeric Antigen Receptor T-cell Therapy for Refractory Systemic Lupus Erythematosus and Systemic SclerosisShlomit Kfir-Erenfeld, Shlomo Elias, Nathalie Asherie, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2024
Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple MyelomaNico Gagelmann, Danai Dima, Maximilian Merz, et al.
Pageof 4

Showing results (31-40 of 36) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
Haematologica|July 2, 2016
Specific antibody deficiency and autoinflammatory disease extend the clinical and immunological spectrum of heterozygous NFKB1 loss-of-function mutations in humansCyrill Schipp, Schafiq Nabhani, Kirsten Bienemann, et al.
International Journal of Molecular Sciences|April 14, 2026
Viral Reactivation in Multiple Myeloma Patients Receiving Anti-BCMA Chimeric Antigen Receptor T-Cell TherapyIdo Cohen, Eyal Lebel, Sigal Grisariu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 9, 2024
Efficacy and Safety of Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T-Cell for the Treatment of Relapsed and Refractory AL AmyloidosisEyal Lebel, Nathalie Asherie, Shlomit Kfir-Erenfeld, et al.
Blood Advances|May 20, 2024
Clinical evaluation and determinants of response to HBI0101 (BCMA CART) therapy in relapsed/refractory multiple myelomaShlomit Kfir-Erenfeld, Nathalie Asherie, Eyal Lebel, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 7, 2026
B-cell Maturation Antigen Targeted Chimeric Antigen Receptor T-cell Therapy for Refractory Systemic Lupus Erythematosus and Systemic SclerosisShlomit Kfir-Erenfeld, Shlomo Elias, Nathalie Asherie, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2024
Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple MyelomaNico Gagelmann, Danai Dima, Maximilian Merz, et al.
Pageof 4